Medifast Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

1 Wall Street research analysts have issued 12 month price targets for Medifast's stock. Their MED stock forecasts range from $352.00 to $352.00. On average, they predict Medifast's share price to reach $352.00 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $209.43 at the start of the year. Since then, MED stock has decreased by 12.0% and is now trading at $184.25.
View the best growth stocks for 2022 here.

Medifast saw a increase in short interest in June. As of June 15th, there was short interest totaling 989,100 shares, an increase of 71.8% from the May 31st total of 575,700 shares. Based on an average trading volume of 117,700 shares, the days-to-cover ratio is presently 8.4 days. Currently, 8.7% of the company's stock are short sold.
View Medifast's Short Interest.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Medifast.

Medifast, Inc. (NYSE:MED) posted its quarterly earnings data on Monday, May, 2nd. The specialty retailer reported $3.59 earnings per share for the quarter, topping the consensus estimate of $3.56 by $0.03. The specialty retailer earned $417.60 million during the quarter, compared to analyst estimates of $415.20 million. Medifast had a trailing twelve-month return on equity of 81.42% and a net margin of 10.28%.
View Medifast's earnings history.

Medifast declared a quarterly dividend on Saturday, June 18th. Stockholders of record on Tuesday, June 28th will be given a dividend of $1.64 per share on Monday, August 8th. This represents a $6.56 annualized dividend and a yield of 3.56%. The ex-dividend date is Monday, June 27th.
View Medifast's dividend history.

Medifast(NYSE:MED) pays an annual dividend of $6.56 per share and currently has a dividend yield of 3.50%. Medifast has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio of Medifast is 46.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 33.88% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

Medifast updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $14.60-$16.05 for the period, compared to the consensus EPS estimate of $15.62. The company issued revenue guidance of $1.78 billion-$1.84 billion, compared to the consensus revenue estimate of $1.77 billion.

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medifast include Estée Lauder Companies (EL), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Veru (VERU), Revlon (REV) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $184.25.

Medifast (NYSE:MED) has a market capitalization of $2.12 billion and generates $1.53 billion in revenue each year. The specialty retailer earns $164.03 million in net income (profit) each year or $14.02 on an earnings per share basis.

Medifast employs 984 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for Medifast is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.